BIOLIFE SOLUTIONS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BLFS in the last 30 days.
See all $BLFS insider activity →BioLife Solutions (BLFS) ceased trading on Nasdaq on Oct 6, 2026, following its merger with Repligen. The company requested delisting and deregistration of its common stock, and plans to terminate reporting obligations. Trading was halted post-market on Oct 5, 2026.
BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea
Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning BLFS (BIOLIFE SOLUTIONS INC). Coverage has skewed bearish: 0 bullish, 5 neutral, and 1 bearish.
Recent BLFS coverage spans mergers & acquisitions, market movers and financial news.
The delisting notice is expected to drive the stock lower as investors react to loss of Nasdaq listing and reduced liquidity.
BLFS will cease trading; shareholders receive RGEN shares and cash, likely causing sell pressure on BLFS and upside for RGEN.
BioLife will cease to be a public company; shareholders are paid, removing the ticker from trading.
Share price likely moves toward the $11.25 cash + 0.1442 RGEN shares offer.
Acquisition news drives strong upside.
AlphAI scores every news story that mentions BLFS with an AI model for sentiment and relevance, and aggregates insider trades from BIOLIFE SOLUTIONS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioLife Solutions (BLFS) ceased trading on Nasdaq on Oct 6, 2026, following its merger with Repligen. The company requested delisting and deregistration of its common stock, and plans to terminate reporting obligations. Trading was halted post-market on Oct 5, 2026.
1 min readBIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea
2 min readRepligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.
1 min readS&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.
3 min readOmeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
2 min readBioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.
2 min readRepligen (RGEN) filed an amended Form S-4 to register shares for its acquisition of BioLife Solutions. The deal offers $11.25 in cash plus 0.1442 Repligen shares per BioLife share, pending approvals. The merger is subject to shareholder and regulatory approvals, with a special meeting scheduled for October 5, 2026. The exchange ratio is fixed, but the value of the share portion will fluctuate with Repligen's stock price.
2 min readBiotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
5 min readBioLife Solutions, Inc. (BLFS) reported Q2 2026 sales of $28.47M, up from $23.44M, and shifted from a net loss of $15.84M to net income of $45.10M. Basic EPS from continuing operations improved from -$0.32 to $0.92. The article also discusses a pending $1.6B Repligen acquisition and forecasts $161.3M revenue and $33.2M earnings by 2028.
6 min readSimply Wall St reports BioLife Solutions (BLFS) swung from a prior net loss to net income of $45.1 million in Q2, with sales of $28.47 million, after its 6 Aug 2026 earnings report. The stock rose 22.97% over 30 days and 69.70% over 90 days. The article cites BLFS trading at a 35x P/E versus a SWS fair P/E of 15.6x and DCF value of $38.22 (about 7.8% above $35.23).
6 min read
